drugset / Trial / NCT01114529
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients
Timeline
- Start
- 2010-08-09
- Primary completion
- 2014-10-30
- Completion
- 2014-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Comparator | Tacrolimus | Small molecule | — | — |
Indications
No indication recorded.